Use and safety of antipsychotic drugs during pregnancy

Journal of Psychiatric Practice

Volumn 15, Issue 3, 2009, Pages 183-192

  Einarson, Adrienne ^a   Boskovic, Rada ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adverse outcomes; atypical antipsychotics; Bipolar disorder; Birth defects; Conventional antipsychotics; Fetal toxicity; First generation antipsychotics; Nausea; Pregnancy; Schizophrenia; Second generation antipsychotics; Teratogenicity; Vomiting weight gain

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROCHLORPERAZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ACHONDROPLASIA; ARTICLE; BIPOLAR DISORDER; BIRTH DEFECT; CARDIOVASCULAR MALFORMATION; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FIRST TRIMESTER PREGNANCY; HUMAN; HYPEREMESIS GRAVIDARUM; HYPERPROLACTINEMIA; HYPOTENSION; LIMB MALFORMATION; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; NERVE CELL DIFFERENTIATION; NONHUMAN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SKELETON MALFORMATION; SPONTANEOUS ABORTION; TARDIVE DYSKINESIA; TERATOGENICITY; TREMOR; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ABNORMALITIES, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPEREMESIS GRAVIDARUM; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 67650353988     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000351878.45260.94     Document Type: Article

References (53)

1. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000;401: 3-38.
2. Howard LM. Fertility and pregnancy in women with psychotic disorders. Eur J Obstet Gynecol Reprod Biol 2005; 119:3-10.
3. Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 1997;23: 623-35.
4. Miller LJ, Finnerty M. Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. J Psychosom Obstet Gynaecol 1998;19: 210-7.
5. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: A meta-analysis of case-control studies. Psychol Med 1996;26: 279-87.
6. Howard LM, Goss C, Leese M, et al. Medical outcome of pregnancy in women with psychotic disorders and their infants in the first year after birth. Br J Psychiatry 2003; 182:63-7.
7. Nilsson E, Lichtenstein P, Cnattingius S, et al. Women with schizophrenia: Pregnancy outcome and infant death among their offspring. Schizophr Res 2002; 58:221-29.
8. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74.
9. Tondo L, Isacsson G, Baldessarini RJ. Suicidal behavior in bipolar disorder: Risk and prevention. CNS Drugs 2003; 17:491-511.
10. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005;62:617-27.
11. Grof P, Robbins W, Alda M, et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000;61:31-9.
12. Pugh TF, Jerath BK, Schmidt WM, et al. Rates of mental disease related to childbearing. N Engl J Med 1963;268: 1224-8.
13. Sharma V. Management of bipolar II disorder during pregnancy and the postpartum period - Motherisk update 2008. Can J Clin Pharmacol 2009;16:e33-41
14. Viguera AC, Cohen LS, Bouffard S, et al. Reproductive decisions by women with bipolar disorder after prepreg-nancy psychiatric consultation. Am J Psychiatry 2002; 159: 2102-4.
15. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49-55.
16. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-84.
17. Badell M, Ramin S, Smith J. Treatment options for nau- sea and vomiting during pregnancy. Pharmacotherapy 2006; 26:1273-87.
18. Shepard TH. Catalog of teratogenic agents. 10th ed. Baltimore: Johns Hopkins University Press; 2001.
19. Schaefer C. Angiotensin II-receptor antagonists: Further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003;67:591-4.
20. Einarson A. Studying the safety of drugs in pregnancy: And the gold standard is? Journal of Clinical Pharmacology and Pharmacoepidemiology 2008;1:3-8.
21. Dixon LB, Lehman AF, Levine J. Conventional antipsy-chotic medication for schizophrenia. Schizophr Bull 1995; 21:567-77.
22. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. Am J Obstet Gynecol 1977; 128: 486-8.
23. O'Connor M, Johnson GH, James DI. Intrauterine effects of phenothiazines. Med J Aust 1981;1:416-7.
24. Czeizel A, Szegal B, Joffe J. The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol 1999;21:157-67.
25. Hannah R, Roth S, Spira A. The effects of chlorpromazine and phenobarbital on vasculogenesis in the cerebellar cortex. Acta Neuropathol 1982;57:306-8.
26. Farkas V, Farkas G. Teratogenic action of hyperemesis in pregnancy and of medication used to treat it. Zentralbl Gynakol 1971;10:325-30.
27. Auerbach J, Hans J, Marcus S, et al. Maternal psy-chotropic medication and neonatal behavior. Neurotoxicol Teratol 1992;14:399-406.
28. Rafla N. Limb deformities associated with prochlorper-azine.Am J Obstet Gynecol 1987;156:1557.
29. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation, eighth edition. Philadelphia: Lippincott, Williams and Wilkins; 2008.
30. Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study. J Clin Psychiatry 2005;66: 317-22.
31. Canadian Department of National Health and Welfare, Food and Drug Directorate. Letter of notification to Canadian physicians. Ottawa; December 7, 1962.
32. Moriarty AJ. Trifluoperazine and foetal abnormalities. Can Med Assoc J 1963;88:97.
33. Heel RC, Brogden RN, Speight TM, et al. Loxapine: A review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978;15: 198-217.
34. Cleary MF. Fluphenazine decanoate during pregnancy. Am J Psychiatry 1977;134:815-6.
35. Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia. Expert Rev Neurother 2004; 4:705-23.
36. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005; 66:444-9, quiz 546.
37. Reis M, Ks̈llen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
38. MacRitchie K, Young AH, McElhatton P. Birth outcome following therapeutic atypical antipsychotics exposure during pregnancy: An ongoing prospective study. Clin Toxicol 2006;44:A84.
39. Newham JJ, Thomas SH, Macritchie K, et al. Birthweight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study. Br J Psychiatry 2008;192:333-7.
40. Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: Pregnancy and neonatal outcomes. Drug Saf 2007; 30:247-64.
41. Kim SW, Kim KM, Kim JM, et al. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:543-5.
42. Daniel DG, Copeland LF. Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 2000;9:819-28.
43. Weisenburger WP, Medeiros LA, Chapin DS, et al. Developmental neurobehavioral evaluation of a new anti-psychotic, ziprasidone, in rats. Neurotoxicol Teratol 1995; 17:386.
44. Product information. (Abilify) Otsuka America Pharmaceuticals 2004.
45. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006; 8:299-300.
46. Mendhekar D, Sharma J, Srilakshmi P. Use of aripipra-zole during late pregnancy in a woman with psychotic illness. Ann Pharmacother 2006;40:575.
47. Henderson DC. Weight gain with atypical antipsychotics: Evidence and insights. J Clin Psychiatry 2007;68:18-26.
48. Scialli AR, Public Affairs Committee of the Teratology Society. Teratology public affairs committee position paper: Maternal obesity and pregnancy. Birth Defects Res A Clin Mol Teratol 2006;76:73-7.
49. Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood: Associations with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115:290-6.
50. Anderson JL, Waller DK, Canfield MA, et al. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiology 2005;16:87-92.
51. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs due to fears of teratogenic risk and the impact of counseling. J Psychiatry Neurosci 2001;26: 44-8.
52. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61: 833-40.
53. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980;97:308-10.